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Background: One of the problems in prostate cancer (CaP) treatment is the appearance of the 
multidrug resistance phenotype, in which ATP-binding cassette transporters such as multidrug 
resistance protein 1 (MRP1) play a role. Different localizations of the transporter have been 
reported, some of them related to the chemoresistant phenotype.
Aim: This study aimed to compare the localization of MRP1 in three prostate cell lines 
(normal, androgen-sensitive, and androgen-independent) in order to understand its possible 
role in CaP chemoresistance.
Methods: MRP1 and caveolae protein markers were detected using confocal microscopy, per-
forming colocalization techniques. Lipid raft isolation made it possible to detect these proteins 
by Western blot analysis. Caveolae and prostasomes were identified by electron microscopy.
Results: We show that MRP1 is found in lipid raft fractions of tumor cells and that the number 
of caveolae increases with malignancy acquisition. MRP1 is found not only in the plasma 
membrane associated with lipid rafts but also in cytoplasmic accumulations colocalizing with 
the prostasome markers Caveolin-1 and CD59, suggesting that in CaP cells, MRP1 is localized 
in prostasomes.
Conclusion: We hypothesize that the presence of MRP1 in prostasomes could serve as a reser-
voir of MRP1; thus, taking advantage of the release of their content, MRP1 could be translocated 
to the plasma membrane contributing to the chemoresistant phenotype. The presence of MRP1 
in prostasomes could serve as a predictor of malignancy in CaP.
Keywords: prostate cancer, MRP1, Caveolin-1, lipid rafts, caveolae, prostasomes
Introduction
In the developed world, prostate cancer (CaP) is the most common non-skin cancer in 
men (899,000 new cases each year) and the fifth most common cancer overall. Nearly 
three-quarters of registered cases occur in developed countries (64,000 cases), and it 
is estimated to be the second leading male cancer in Spain in 2015.1
Localized CaP is the most commonly diagnosed stage. However, metastatic CaP still 
remains a major oncological problem in its follow-up. Despite initial response, most 
tumors relapse within 2 years to an incurable androgen-independent state.2
Chemotherapy is the main treatment to deal with hormonoresistant metastatic 
CaP. Unfortunately, CaP is also resistant to a broad range of antineoplastic agents, 
a phenomenon known as multidrug resistance (MDR) phenotype,3,4 which plays an 
important role in the progressive resistant phenotype observed in CaP.
One of the mechanisms leading to the MDR phenotype is the activation of efflux 
proteins belonging to the ATP-binding cassette (ABC) transporter superfamily;5 
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P-glycoprotein (Pgp)6 and the multidrug resistant protein 1 
(MRP1) are members of this family with a putative role 
in CaP chemoresistance.7 Although ABC transporters are 
mainly localized in the plasma membrane,8 some of them 
have also been described in other cellular localizations such 
as lysosomes,9 cytoplasmic vesicles,10,11 and secretory vesi-
cles putatively derived from the Golgi apparatus.5,12,13 A more 
recent localization of ABC transporters is in specific regions 
of the plasma membrane rich in cholesterol and sphingolip-
ids, called lipid rafts. Several functions have been attributed to 
lipid rafts such as signal transduction,14 vesicle trafficking,15,16 
and cell adhesion and motility.17 There is strong evidence that 
the lipid composition of biological membranes is closely 
related to the presence of ABC transporters.6,18–20 In the case 
of MRP1, there are some controversies about the presence 
of this transporter in lipid rafts.21–23
A subset of lipid rafts is found in cell surface invagina-
tions known as caveolae. Caveolae are formed from lipid 
rafts by polymerization of caveolins, integral membrane 
proteins that tightly bind cholesterol.24 Elevated expression 
of caveolin-1 (Cav-1) is accompanied by the acquisition 
of MDR in various chemotherapy-resistant prostate tumor 
cells25 and has been found in late stages of CaP progression.26 
Cav-1 is secreted by CaP cells, and the results of recent stud-
ies showed that secreted Cav-1 can stimulate cell survival and 
angiogenic activities, defining a role for Cav-1 in the CaP 
microenvironment.27–30
Additionally, Cav-1 has also been related to prostasomes, 
secretory granules stored and released by the glandular epi-
thelial prostate cells. Cav-1 has been observed in prostasomes 
of the prostate cancer cell 3 line (PC3) human CaP cell line 
together with CD59,31 a specific marker of these vesicles. 
Prostasomes have also been related to cell transformation, 
proliferation, and angiogenesis.32–35
In addition, there are studies that suggest that prostasomes 
may be implicated in CaP, and they are proposed as a prog-
nostic indicator of tumor progression.36
Our studies have been focused on the analysis of a new 
localization for MRP1. We show that MRP1 is localized both 
in cytoplasmic accumulations and in plasma membranes of 
cell lines colocalizing with Cav-1. We also found MRP1 
together with Cav-1 in lipid rafts, and this localization is more 
obvious in the cancer cell lines. The presence of caveolae is 
more abundant in the cancer cell lines compared with the 
normal cell line. Finally, we have demonstrated that MRP1 
colocalizes with Cav-1 and CD59 in the accumulations found 
in the cytoplasm, concluding that MRP1 is found in prosta-
somes. The function of MRP1 in prostasomes needs to be 
studied in more detail, but one of the hypotheses we propose 
is that prostasomes could serve as a reservoir/storage of MRP1 
and, taking advantage of the fusion of prostasomes to the 
plasma membrane, MRP1 could be transported to the plasma 
membrane, participating in the development of CaP.
Methods
cell culture
The normal human prostate epithelial cell line (PNT2) was 
provided by Dr Maitland (YCR Cancer Research Unit, 
University of York). The two tumor cell lines used were 
the androgen-dependent cell line lymph node carcinoma of 
the prostate (LNCaP) and the androgen-independent cell 
line PC3, both provided by The Prostate Center (Vancouver, 
Canada). All three cell lines were maintained at 37°C in a 
5% CO
2
 atmosphere and cultured in Roswell Park Memorial 
Institute (RPMI) 1640 supplemented with inactivated 10% 
fetal bovine serum, 1% l-glutamine, and 1% penicillin–
streptomycin (Biological Industries, Israel Beit Haemek 
LTD). All cell cultures were mycoplasma free. Cancer cell 
lines LNCaP and PC3 derive from metastasis to lymph nodes 
and bone, respectively (American Type Culture Collection 
[ATCC], Manassas, VA, USA). They present intrinsic MDR 
phenotype, expressing MRP1, and acquired MDR when 
exposed to increasing doses of chemotherapeutics.
isolation of lipid rafts
Lipid rafts were isolated from 5×107 cells of each cell line. 
Pelleted cells were disrupted with 1 mL of raft II buffer 
(50 mM Tris HCl pH =8.0, 10 mM MgCl
2
, 0.15 M NaCl, 
1% Triton X-100, 5% Glycerol, 50 mM PMSF, 25× cocktail 
of protease inhibitors [Complete™ EDTA-free; Biological 
Industries, Israel Beit Haemek LTD] [to a final 1× concentra-
tion] and 0.03% of β-mercaptoethanol). The disrupted pellet 
was centrifuged at 500× g for 5 minutes at 4°C. The superna-
tant was transferred into a 15 mL falcon tube and rotated for 
1 hour at 4°C. Afterward, 1 mL of raft I buffer (50 mM Tris 
HCl pH =8, 10 mM MgCl
2
, 0.15 M NaCl) containing 80% 
sucrose was added to achieve a final concentration of 40% 
sucrose, followed by 7.5 mL of the same buffer containing 
38% sucrose and 2 mL of buffer with 15% sucrose, thereby 
achieving a discontinuous sucrose gradient.
Finally, the gradient was ultracentrifuged at 100,000× g 
for 18 hours at 4°C in a SW41 rotor (Ti70 Beckman rotor). 
Fractions of 1 mL (12 fractions) were collected from the 
top of the gradient to the bottom (F1–F12 respectively). 
Immunoblot analysis was performed to confirm the fractions 
that contained lipid raft microdomains.
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The isolation of lipid rafts was performed at least three 
times from three independent biological replicates to ensure 
reproducibility.
Western blot analysis
Fractions obtained from the sucrose gradient were analyzed 
by SDS/PAGE on 7.5% or 12% (w/v) gel, transferred onto 
a nitrocellulose membrane, blocked in 5% nonfat dry milk 
and 0.05% Tween-20 in phosphate buffered saline (PBS). The 
primary antibodies used were Cav-1 (BD Transduction Labo-
ratories), MRP1 (provided by Dr G Sheffer and Dr R Skepper 
of Free University  Medical Center, Amsterdam, the Nether-
lands), and Flotillin-1 (BD Transduction Laboratories). Sec-
ondary antibodies were HRP-conjugated goat antimouse and 
goat antirat immunoglobulin, and the blots were developed 
using the ECL Western blotting kit (Amersham Biosciences) 
and visualized using LAS-3000 Fujifilm.
confocal microscopy
Cells were grown in 24-well plates on sterilized coverslips. 
Fixation and permeabilization was with methanol (-20°C 
for 3 minutes), followed by two washes with PBS and 
blocked with 0.2% bovine serum albumin. The cells 
were incubated for 1 hour at room temperature (RT) 
with Cav-1 (1/500), MRP1 (1/200), or CD59 (1/1,000) 
(Exbio antibodies). After three washes with PBS, cells 
were incubated with: Alexa Fluor® 488 goat antirat IgG 
(molecular probes; Invitrogen) (1/400), Cys™3 conjugated 
Affini Pure, fragment donkey antimouse IgG (Jackson 
 ImmunoResearch, Laboratories, Inc, West Grove, PA, 
USA) (1/500), for 45 minutes at RT. The nuclei were 
stained with Topro III (Calbiochem) for 30 minutes at RT. 
Controls were done incubating the fixed cells with only 
the secondary antibodies. Finally, the cells were mounted 
on Mowiol (Calbiochem-Novabiochem) and visualized in 
a Leica TCS-SL confocal microscope.
MRP1 quantification
To quantify the presence of MRP1 in both the membrane 
and the cytoplasm, the images from the confocal micros-
copy were examined and assessed by two investigators 
 independently. By prior agreement, the intensity of MRP1 
antibody was scored depending on the staining of cells in 
strongly  positive (+++), moderate (++), or weak (+) staining. 
To obtain a numerical value with which to do the statistical 
analysis, a constant =1 has been added to the number of + 
and has been multiplied by the percentage of stained cells. 
For instance: a sample that has stained 30% of the cells with 
moderate intensity (++) would be: (2 + 1) × 30 = 90. Statistical 
analyses were performed using the Mann–Whitney U test.
electron microscopy
Cell monolayers were fixed with 2.5% glutaraldehyde in 0.1 M 
PBS for 2 hours at 4°C. Cells were gently scraped,  collected, 
and pelleted by centrifugation (5 minutes at 500× g). After 
three rinses in 0.1 M PBS, pellets were postfixed in 1% OsO
4
 
-0.8% FeCNk for 90 minutes at RT. Finally, the three cell 
lines were embedded in Spurr resins (Sigma-Aldrich Co, St 
Louis, MO, USA), and ultrathin sections were analyzed with 
a Jeol1010 electron microscope. Grids were systematically 
screened, and the number of both caveolae and prostasomes 
was determined in random fields of sections from images 
acquired at the same magnification (25,000×). The images 
were examined and assessed by three investigators indepen-
dently. For each cell line, over ten cells were examined with 
an estimated total linear surface of 500 µm. Finally, for each 
cell line an average number of caveolae/µm2 and prostasomes/
µm2 perimeter was calculated. Statistical analyses were per-
formed using the Mann–Whitney U test.
Results
localization of MrP1 in prostate  
cancer cell lines
MRP1 was localized through immunocytochemistry 
 techniques in two cellular compartments, with different 
distributions in normal versus cancer cell lines. In the nor-
mal PNT2 cell line, MRP1 was mainly localized in plasma 
membrane, more in some areas than others (Figures 1A, 2A, 
and 3A). On the other hand, in the cancer cell lines, MRP1 
was observed not only in plasma membrane but also in cyto-
plasm regions (Figures 1B, C, 2D, G, 3D and J). These results 
were confirmed when the staining of MRP1 was quantified 
both in the membrane and in the cytoplasm of the three cell 
lines: the PNT2 cell line had more staining of MRP1 in the 
membrane (190.2±46.7) than in the cytoplasm (0.25±0.5). In 
addition, compared with malignant prostate cell lines, mem-
brane MRP1 staining was higher in PNT2 than in LNCaP 
and PC3 (118.75±14.6 [P=0.029] and 98.7±12.7 [P=0.020], 
respectively), whereas in the cytoplasm, MRP1 expression 
was higher in LNCaP and PC3 cells (33±12.3 [P=0.019] and 
22±6.9 [P=0.017], respectively).
localization of MrP1 in lipid raft domains
We analyzed the presence of MRP1 in lipid raft regions of 
the three cell lines. To that purpose, confocal microscopy was 
applied using Cav-1 as a typical lipid raft marker.
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Figure 1 MrP1 localization in prostate cell lines.
Notes: (A) The aBc transporter was mainly localized in plasma membrane in the 
normal prostate cell line PnT2. Prostate cancer cell lines (B) lncaP and (C) Pc3 
also showed cytoplasmic MrP1 accumulations cell lines.
Abbreviations: MrP1, multidrug resistance protein 1; aBc, aTP-binding cassette; 
PnT2, normal human prostatic epithelial cell line; lncaP, lymph node carcinoma of 
the prostate; Pc3, prostate cancer cell 3 line.
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Cav-1 expression was found in plasma membrane of 
the three cell lines, and also in cytoplasm accumulations 
in the case of LNCaP and PC3 (Figure 2B, E, and H; 
Figure 4A, D, G, J, and N). When a merging of MRP1 and 
Cav-1 images was done, the two proteins colocalized both in 
the plasma membrane, especially in PNT2 (Figure 2C), and 
cytoplasm accumulations in LNCaP (Figure 2F) and PC3 
(Figure 2I). Similar results were obtained when perform-
ing colocalization assays with Flotillin-1, another lipid raft 
marker (data not shown).
To verify the presence of MRP1 in lipid raft domains 
together with Cav-1, lipid rafts were isolated followed by 
MRP1 and Cav-1 detection in the different fractions (F) 
obtained (Figure 5). In all cell lines, Cav-1 localized in a 
different grade in the fractions that corresponded to lipid raft 
(F1–3), where Flotillin-1 (Flot-1), a protein also found in lipid 
rafts, was present. In PNT2, most of the MRP1 was observed 
in the soluble fractions (F5–12) and also in small amounts 
in the last fraction (slightly in F2, and mainly in F3) (Figure 
5A). In LNCaP, MRP1 started to be detected in early insoluble 
fractions corresponding to lipid rafts (mainly in F3), and, 
similarly to PNT2, most MRP1 was found in more soluble 
fractions (F3 and on) (Figure 5B). By contrast, MRP1 entirely 
localized in the lipid raft fractions of PC3 (F1–2) and, to a 
lesser extent, in the soluble fractions (Figure 5C).
Presence of lipid raft-related structures: 
caveolae and prostasomes
The presence of caveolae was detected in PNT2 (Figure 6A 
and B), LNCaP (Figure 6D and E), and PC3 (Figure 6G 
and H). The number was counted, and the ratio between the 
number and the perimeter of the cells was obtained. CaP 
cell lines contained twice as many caveolae as the normal 
prostate cell line (Table 1).
Due to the fact that MRP1 and Cav-1 also colocalized 
in cytoplasm accumulations (Figure 2), and that lipid rafts 
are related to prostasomes,31 the presence of prostasomes 
was also analyzed by electron microscopy. The three cell 
lines showed prostasomes, structures formed of vesicles 
approximately 0.5 µm containing an electron-lucent sub-
stance and small vesicles and dense bodies in the inside 
(Figure 6C, F, and I). The shape of the storage vesicles was 
mostly circular. Two kinds of prostasomes were observed: 
“dense” prostasomes often filled with small dark particles 
or inclusions (Figure 6C and F), and “clear” prostasomes 
filled with less electro dense content. Prostasomes had thin 
flexible walls, which rendered them irregular in outline 
in those cellular areas where the vesicles were crowded 
(Figure 6I). When the number of prostasomes was counted, 
the androgen-independent and thus more aggressive PC3 cell 
line displayed a higher number of prostasomes compared 
with the other two cell lines (the ratio of prostasomes/µm2 
was 2.77, 2.75, and 3.76 in the PNT2, LNCaP, and PC3 cell 
lines, respectively), the differences between the PNT2 and the 
PC3 cell lines being statistically significant (P,0.01).
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MRP1
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E F
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Cav-1 Merge
Figure 2 colocalization of MrP1 and cav-1 in the three cell lines.
Notes: (A–C) PnT2, (D–F) lncaP, and (G–I) Pc3 using confocal microscopy. MrP1 and cav-1 colocalized in caP cells in some regions of the plasma membrane and in 
cytoplasmic accumulations (F and I). a few colocalizations were found in the plasma membrane of normal prostate cells (C).
Abbreviations: MrP1, multidrug resistance protein 1; cav-1, caveolin-1; caP, prostate cancer; PnT2, normal human prostatic epithelial cell line; lncaP, lymph node 
carcinoma of the prostate; Pc3, prostate cancer cell 3 line.
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localization of MrP1 in prostasomes
To verify the presence of Cav-1 in prostasomes of tumor cell 
lines, colocalization studies of Cav-1 and CD59 (a positive 
marker of prostasomes) were performed in PNT2, LNCaP, 
and PC3 (Figure 4). As already observed, Cav-1 was local-
ized in the plasma membrane of PNT-2 (Figure 2), where 
some portions of the membrane presented stronger staining 
(Figure 4A). CD59 was also present in the plasma membrane, 
and some cells had some specific dots in the cytoplasm 
(Figure 4B). But the merge showed that in general, there 
was no colocalization (Figure 4C). In LNCaP and PC3, 
Cav-1 was found along the plasma membrane, stronger 
in specific regions than in others (Figure 4D, G and J, N, 
respectively) and, in contrast to PNT2, it was also found in 
cytoplasmic regions (Figure 4A). CD59 was found along 
the plasma membrane, also stronger in some regions and in 
cytoplasmic accumulations (Figure 4E, H, L, and O). Cav-1 
and CD59 colocalized in both cancer cell lines, in regions of 
the membrane where the individual staining for each of the 
proteins was strongest (Figure 4I and P). The cytoplasmic 
accumulations where Cav-1 and CD59 colocalized were, in 
most cases, close to the plasma membrane, although in a few 
cases these accumulations were not close to it (Figure 4F 
and upper left M).
The next step was to analyze if the cytoplasmic accumula-
tions where Cav-1 and MRP1 colocalized were prostasomes, 
and for that purpose, the prostasome marker CD59 was used.
In PNT2, MRP1 and CD59 were localized only in 
the plasma membrane, with stronger staining in specific 
membrane regions (Figure 3A and B). CD59 was expressed 
only in some cells as nonhomogeneous cytoplasmic accumu-
lations, and in these localizations, Cav-1 did not colocalize 
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Figure 3 Presence of MrP1 in prostasomes.
Notes: colocalizations of MrP1 with the prostasome marker cD59 were performed to detect the aBc-transporter in these structures. localization of MrP1 (green) in 
PnT2 (a), lncaP (D and g), and Pc3 (J and M) cell lines; localization of cD59 (red) in PnT2 (B), lncaP (e and h), and Pc3 (K and n) cell lines. MrP1 colocalized with 
cD59 in cytoplasmic accumulations in the cancer cell lines lncaP (F and i) and Pc3 (l and O) whereas it did not colocalize in the normal cell line PnT2 (c).
Abbreviations: MrP1, multidrug resistance protein 1; aBc, aTP-binding cassette; lncaP, lymph node carcinoma of the prostate; Pc3, prostate cancer cell 3 line; 
PnT2, normal human prostatic epithelial cell line.
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with MRP1 (Figure 3C). Thus, in PNT2, MRP1 was not found 
in prostasomes. In LNCaP, MRP1 and CD59 were found in 
the plasma membrane (Figure 3D, E, G, and H) but not in a 
continuous way; curiously, the regions positive for MRP1 
within a cell were negative for CD59, and all the way around. 
There were also some cytoplasmic accumulations where both 
proteins colocalized (Figure 3F and I). This colocalization was 
very specific and observed only in a few cells. Finally, in PC3, 
MRP1 and CD59 were found along the plasma membrane 
in continuous staining in all cells (Figure 3J, K, M, and N). 
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Figure 4 Presence of cav-1 in prostasomes.
Notes: colocalization studies of cav-1 were performed in the three prostate cell lines using cD59, a prostasome marker. cav-1 (green) was present in normal prostate cell 
line PnT2 (a) and in the cancer cell lines lncaP (D and g) and Pc3 (J and M). cD59 (red) was also present in PnT2 (B), lncaP (e and h) and Pc3 (K and n) cell lines. 
neither cav-1 nor cD59 was found in prostasomes in the PnT2 cell line (c), while a colocalization of cav-1 and cD59 was found in caP lncaP cells (F and i) and in greater 
proportion in the androgen independent caP cell line Pc3 (l and O), indicating that in caP cells cav-1 is localized in cD59 positive structures, known as prostasomes.
Abbreviations: cav-1, caveolin-1; caP, prostate cancer; PnT2, normal human prostatic epithelial cell line; lncaP, lymph node carcinoma of the prostate; Pc3, prostate 
cancer cell 3 line.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2221
MrP1 localization in lipid raft domains
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
://
ww
w.
do
ve
pr
es
s.
co
m
/ b
y 
16
1.
11
6.
20
9.
13
7 
on
 1
0-
De
c-
20
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
                             7 / 11
 OncoTargets and Therapy 2014:7
Lipid raft
enriched fraction
CT
MRP1
A
B
C
Flot-1
Cav-1
MRP1
Flot-1
Cav-1
MRP1
Flot-1
Cav-1
F1 F2 F3 F5 F7 F9 F11 F12
CT F1 F2 F3 F5 F7 F9 F11 F12
CT F1 F2 F3 F5F4 F6 F7 F9F8 F10 F11
Figure 5 lipid raft isolation from the three prostate cell lines.
Notes: (A) lipid raft enriched fractions were isolated from the normal cell line PnT2 and showed MrP1 was present only in the last lipid raft enriched fraction, enriched 
with cav-1. (B) When lipid raft fractions were isolated from the androgen-sensitive prostate cancer cell line lncaP, MrP1 was already detected in early lipid raft enriched 
fractions together with cav-1 (F1–F2) and in greater amounts in a later lipid raft enriched fraction (F3). Both PnT2 and lncaP cells presented soluble fractions of MrP1 
(F5–F11). (C) Lipid raft enriched fractions isolated from the androgen-independent prostate cancer cell line PC3 showed the presence of MRP1 mainly in the first two 
fractions (F1–F2). Flotillin-1 (Flot-1) was used as a control of the lipid raft isolation.
Abbreviations: PnT2, normal human prostatic epithelial cell line; MrP1, multidrug resistance protein 1; cav-1, caveolin-1; lncaP, lymph node carcinoma of the prostate; 
Pc3, prostate cancer cell 3 line.
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In a quarter of the cells observed, both proteins were also 
found in cytoplasmic accumulations where both colocalized 
(Figure 3L and O). Thus, in LNCaP and PC3, MRP1 colocal-
ized in CD59 positive cytoplasmic regions, also positive for 
Cav-1, markers typically used to describe prostasomes.
Discussion
The present study is focused on the cellular localization of 
MRP1 in CaP cancer cells with particular attention to lipid rafts. 
Lipid rafts lead to plasma membrane invaginations called 
caveolae, and cytoplasmic vesicles called prostasomes. 
MRP1 was found in the three prostate cell lines, both 
in the plasma membrane and also in the cytoplasm. The 
fact that MRP1 had stronger staining in specific regions 
of the plasma membrane and that previous studies have 
reported the presence of other ABC transporters in lipid 
raft microdomains, led us to investigate the presence of 
MRP1 in these membrane regions. Lipid rafts have been 
implicated in many cellular functions, including protein 
and lipid transport and signal transduction. MRP1 and 
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Figure 6 representative electron micrographs of caveolae and prostasomes in the three prostate cell lines.
Notes: The presence of caveolae (black arrows) was observed in the normal PnT2 cell line (A and B), androgen-sensitive lncaP cell line (D and E), and the androgen-
independent Pc3 cell line (G and H). Prostasomes were also localized in PnT2 (C), lncaP (F), and Pc3 cell lines (I) (white arrows).
Abbreviations: PnT2, normal human prostatic epithelial cell line; lncaP, lymph node carcinoma of the prostate; Pc3, prostate cancer cell 3 line.
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 glucosylceramide have been described to be overexpressed 
and enriched in lipid rafts during the acquisition of the MDR 
phenotype in colon cancer cells.22 We found colocalization 
of Cav-1 and MRP1 in the plasma membrane, suggesting 
that MRP1 could also be localized in lipid rafts in CaP cell 
lines. Lipid raft isolation showed the presence of MRP1 since 
MRP1 was found in Cav-1 (and Flot-1) enriched fractions. 
In addition, MRP1 colocalized with Cav-1 not only in the 
plasma membrane but also in cytoplasmic accumulations. 
This phenomenon was observed only in CaP cell lines and 
not in PNT2, normal prostate cell line. Furthermore, the 
number of caveolae was counted and it was found to be double 
in LNCaP and PC3 compared with PNT-2, as Quest et al. 
observed in 2004.26 MRP1 is known to have a major role in 
CaP.37 Although previous studies described the presence of 
MRP1 in lipid rafts domains38 an extended work needed to 
be done in CaP.
Studies by Llorente et al31 showed that Cav-1 colocalized 
in cytoplasmic accumulations with the prostasome marker 
CD59, in PC3, and concluded that Cav-1 was localized in 
prostasomes. Prostasomes are vesicles/granules secreted 
by prostate epithelial cells to the prostatic fluid that release 
Cav-1, contributing to cell survival and metastasis.25,28,31,39,40 
Our results showed that MRP1 colocalized with Cav-1 
mostly in cytoplasmic accumulations where CD59 was also 
present. Confocal microscopy results of LNCaP and PC3 with 
Cav-1 and CD59 showed that the two proteins colocalized. 
Parallel experiments with MRP1 and CD59 also showed 
a colocalization between the two proteins, suggesting that 
MRP1 was in prostasomes. Our results showed a higher colo-
calization of MRP1 and Cav-1 in the androgen-independent 
PC3 cell line compared with the androgen-sensitive LNCaP 
cell line. Thus, PC3 malignancy seems to be in accordance 
with higher colocalization/expression of the two proteins.
When performing the colocalizations of MRP1 and CD59, 
in LNCaP there was a sort of “mirror effect”: most of the cells 
that expressed MRP1 did not express CD59, and those who 
expressed CD59, did not expressed MRP1, in LNCaP, a small 
percentage of cells presented colocalization of both proteins. 
This could be explained by the fact that perhaps there might be 
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two different populations of cells within LNCaP: those cells 
less aggressive that do not express MPR1 in prostasomes, and 
those cells that have MRP1 in prostasomes colocalizing with 
MRP1, these being more aggressive cells. We could conclude 
that both CD59 and Cav-1 could act as prostasome markers 
when the cells are acquiring malignancy.
The fusion of prostasomes to the plasma membrane could 
enrich the plasma membrane with MRP1 while releasing Cav-
1, contributing to the chemoresistant phenotype.29,41 The pres-
ence of MRP1 in prostasomes could serve as a reservoir of the 
protein. Cancer cells that have more prostasomes would have 
less MRP1 in the plasma membrane, and all the way around.
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